Inhibition of wild-type p53-expressing AML by the novel small molecule HDM2 inhibitor CGM097

Ellen Weisberg, Ensar Halilovic, Vesselina G. Cooke, Atsushi Nonami, Tao Ren, Takaomi Sanda, Irene Simkin, Jing Yuan, Brandon Antonakos, Louise Barys, Moriko Ito, Richard Stone, Ilene Galinsky, Kristen Cowens, Erik Nelson, Martin Sattler, Sebastien Jeay, Jens U. Wuerthner, Sean M. McDonough, Marion WiesmannJames D. Griffin

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The tumor suppressor p53 is a key regulator of apoptosis and functions upstream in the apoptotic cascade by both indirectly and directly regulating Bcl-2 family proteins. In cells expressing wild-type (WT) p53, the HDM2 protein binds to p53 and blocks its activity. Inhibition of HDM2:p53 interaction activates p53 and causes apoptosis or cell-cycle arrest. Here, we investigated the ability of the novel HDM2 inhibitor CGM097 to potently and selectively kill WT p53-expressing AML cells. The antileukemic effects of CGM097 were studied using cellbased proliferation assays (human AML cell lines, primary AML patient cells, and normal bone marrow samples), apoptosis, and cell-cycle assays, ELISA, immunoblotting, and an AML patient-derived in vivo mouse model. CGM097 potently and selectively inhibited the proliferation of human AML cell lines and the majority of primary AML cells expressing WT p53, but not mutant p53, in a target-specific manner. Several patient samples that harbored mutant p53 were comparatively unresponsive to CGM097. Synergy was observed when CGM097 was combined with FLT3 inhibition against oncogenic FLT3-expressing cells cultured both in the absence as well as the presence of cytoprotective stromal-secreted cytokines, as well as when combined with MEK inhibition in cells with activated MAPK signaling. Finally, CGM097 was effective in reducing leukemia burden in vivo. These data suggest that CGM097 is a promising treatment for AML characterized as harboring WT p53 as a single agent, as well as in combination with other therapies targeting oncogene-activated pathways that drive AML.

Original languageEnglish
Pages (from-to)2249-2259
Number of pages11
JournalMolecular Cancer Therapeutics
Volume14
Issue number10
DOIs
Publication statusPublished - Oct 1 2015

Fingerprint

Apoptosis
Cell Line
Mitogen-Activated Protein Kinase Kinases
Cell Cycle Checkpoints
NVP-CGM097
Oncogenes
Immunoblotting
Bone Marrow Cells
Cultured Cells
Cell Cycle
Leukemia
Proteins
Enzyme-Linked Immunosorbent Assay
Cytokines
Therapeutics
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Inhibition of wild-type p53-expressing AML by the novel small molecule HDM2 inhibitor CGM097. / Weisberg, Ellen; Halilovic, Ensar; Cooke, Vesselina G.; Nonami, Atsushi; Ren, Tao; Sanda, Takaomi; Simkin, Irene; Yuan, Jing; Antonakos, Brandon; Barys, Louise; Ito, Moriko; Stone, Richard; Galinsky, Ilene; Cowens, Kristen; Nelson, Erik; Sattler, Martin; Jeay, Sebastien; Wuerthner, Jens U.; McDonough, Sean M.; Wiesmann, Marion; Griffin, James D.

In: Molecular Cancer Therapeutics, Vol. 14, No. 10, 01.10.2015, p. 2249-2259.

Research output: Contribution to journalArticle

Weisberg, E, Halilovic, E, Cooke, VG, Nonami, A, Ren, T, Sanda, T, Simkin, I, Yuan, J, Antonakos, B, Barys, L, Ito, M, Stone, R, Galinsky, I, Cowens, K, Nelson, E, Sattler, M, Jeay, S, Wuerthner, JU, McDonough, SM, Wiesmann, M & Griffin, JD 2015, 'Inhibition of wild-type p53-expressing AML by the novel small molecule HDM2 inhibitor CGM097', Molecular Cancer Therapeutics, vol. 14, no. 10, pp. 2249-2259. https://doi.org/10.1158/1535-7163.MCT-15-0429
Weisberg, Ellen ; Halilovic, Ensar ; Cooke, Vesselina G. ; Nonami, Atsushi ; Ren, Tao ; Sanda, Takaomi ; Simkin, Irene ; Yuan, Jing ; Antonakos, Brandon ; Barys, Louise ; Ito, Moriko ; Stone, Richard ; Galinsky, Ilene ; Cowens, Kristen ; Nelson, Erik ; Sattler, Martin ; Jeay, Sebastien ; Wuerthner, Jens U. ; McDonough, Sean M. ; Wiesmann, Marion ; Griffin, James D. / Inhibition of wild-type p53-expressing AML by the novel small molecule HDM2 inhibitor CGM097. In: Molecular Cancer Therapeutics. 2015 ; Vol. 14, No. 10. pp. 2249-2259.
@article{9bd70460a1884cc990a40a8fa7949235,
title = "Inhibition of wild-type p53-expressing AML by the novel small molecule HDM2 inhibitor CGM097",
abstract = "The tumor suppressor p53 is a key regulator of apoptosis and functions upstream in the apoptotic cascade by both indirectly and directly regulating Bcl-2 family proteins. In cells expressing wild-type (WT) p53, the HDM2 protein binds to p53 and blocks its activity. Inhibition of HDM2:p53 interaction activates p53 and causes apoptosis or cell-cycle arrest. Here, we investigated the ability of the novel HDM2 inhibitor CGM097 to potently and selectively kill WT p53-expressing AML cells. The antileukemic effects of CGM097 were studied using cellbased proliferation assays (human AML cell lines, primary AML patient cells, and normal bone marrow samples), apoptosis, and cell-cycle assays, ELISA, immunoblotting, and an AML patient-derived in vivo mouse model. CGM097 potently and selectively inhibited the proliferation of human AML cell lines and the majority of primary AML cells expressing WT p53, but not mutant p53, in a target-specific manner. Several patient samples that harbored mutant p53 were comparatively unresponsive to CGM097. Synergy was observed when CGM097 was combined with FLT3 inhibition against oncogenic FLT3-expressing cells cultured both in the absence as well as the presence of cytoprotective stromal-secreted cytokines, as well as when combined with MEK inhibition in cells with activated MAPK signaling. Finally, CGM097 was effective in reducing leukemia burden in vivo. These data suggest that CGM097 is a promising treatment for AML characterized as harboring WT p53 as a single agent, as well as in combination with other therapies targeting oncogene-activated pathways that drive AML.",
author = "Ellen Weisberg and Ensar Halilovic and Cooke, {Vesselina G.} and Atsushi Nonami and Tao Ren and Takaomi Sanda and Irene Simkin and Jing Yuan and Brandon Antonakos and Louise Barys and Moriko Ito and Richard Stone and Ilene Galinsky and Kristen Cowens and Erik Nelson and Martin Sattler and Sebastien Jeay and Wuerthner, {Jens U.} and McDonough, {Sean M.} and Marion Wiesmann and Griffin, {James D.}",
year = "2015",
month = "10",
day = "1",
doi = "10.1158/1535-7163.MCT-15-0429",
language = "English",
volume = "14",
pages = "2249--2259",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Inhibition of wild-type p53-expressing AML by the novel small molecule HDM2 inhibitor CGM097

AU - Weisberg, Ellen

AU - Halilovic, Ensar

AU - Cooke, Vesselina G.

AU - Nonami, Atsushi

AU - Ren, Tao

AU - Sanda, Takaomi

AU - Simkin, Irene

AU - Yuan, Jing

AU - Antonakos, Brandon

AU - Barys, Louise

AU - Ito, Moriko

AU - Stone, Richard

AU - Galinsky, Ilene

AU - Cowens, Kristen

AU - Nelson, Erik

AU - Sattler, Martin

AU - Jeay, Sebastien

AU - Wuerthner, Jens U.

AU - McDonough, Sean M.

AU - Wiesmann, Marion

AU - Griffin, James D.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - The tumor suppressor p53 is a key regulator of apoptosis and functions upstream in the apoptotic cascade by both indirectly and directly regulating Bcl-2 family proteins. In cells expressing wild-type (WT) p53, the HDM2 protein binds to p53 and blocks its activity. Inhibition of HDM2:p53 interaction activates p53 and causes apoptosis or cell-cycle arrest. Here, we investigated the ability of the novel HDM2 inhibitor CGM097 to potently and selectively kill WT p53-expressing AML cells. The antileukemic effects of CGM097 were studied using cellbased proliferation assays (human AML cell lines, primary AML patient cells, and normal bone marrow samples), apoptosis, and cell-cycle assays, ELISA, immunoblotting, and an AML patient-derived in vivo mouse model. CGM097 potently and selectively inhibited the proliferation of human AML cell lines and the majority of primary AML cells expressing WT p53, but not mutant p53, in a target-specific manner. Several patient samples that harbored mutant p53 were comparatively unresponsive to CGM097. Synergy was observed when CGM097 was combined with FLT3 inhibition against oncogenic FLT3-expressing cells cultured both in the absence as well as the presence of cytoprotective stromal-secreted cytokines, as well as when combined with MEK inhibition in cells with activated MAPK signaling. Finally, CGM097 was effective in reducing leukemia burden in vivo. These data suggest that CGM097 is a promising treatment for AML characterized as harboring WT p53 as a single agent, as well as in combination with other therapies targeting oncogene-activated pathways that drive AML.

AB - The tumor suppressor p53 is a key regulator of apoptosis and functions upstream in the apoptotic cascade by both indirectly and directly regulating Bcl-2 family proteins. In cells expressing wild-type (WT) p53, the HDM2 protein binds to p53 and blocks its activity. Inhibition of HDM2:p53 interaction activates p53 and causes apoptosis or cell-cycle arrest. Here, we investigated the ability of the novel HDM2 inhibitor CGM097 to potently and selectively kill WT p53-expressing AML cells. The antileukemic effects of CGM097 were studied using cellbased proliferation assays (human AML cell lines, primary AML patient cells, and normal bone marrow samples), apoptosis, and cell-cycle assays, ELISA, immunoblotting, and an AML patient-derived in vivo mouse model. CGM097 potently and selectively inhibited the proliferation of human AML cell lines and the majority of primary AML cells expressing WT p53, but not mutant p53, in a target-specific manner. Several patient samples that harbored mutant p53 were comparatively unresponsive to CGM097. Synergy was observed when CGM097 was combined with FLT3 inhibition against oncogenic FLT3-expressing cells cultured both in the absence as well as the presence of cytoprotective stromal-secreted cytokines, as well as when combined with MEK inhibition in cells with activated MAPK signaling. Finally, CGM097 was effective in reducing leukemia burden in vivo. These data suggest that CGM097 is a promising treatment for AML characterized as harboring WT p53 as a single agent, as well as in combination with other therapies targeting oncogene-activated pathways that drive AML.

UR - http://www.scopus.com/inward/record.url?scp=84946761782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946761782&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-15-0429

DO - 10.1158/1535-7163.MCT-15-0429

M3 - Article

C2 - 26206331

AN - SCOPUS:84946761782

VL - 14

SP - 2249

EP - 2259

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 10

ER -